enfortumab vedotin,pembrolizumab
Astellas,merck,seagen
['blcsm', 'pembro']
ev pembro for cddp unfit patients in #blcsm. 64% orr. 10% cr 90 % nectine 4 expression
#esmo22 looking forward for the phase 3 results in the first line setting 
Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert